Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough Corporation

Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough Corporation

4/24/2008

PARIS -- Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal.

Specifically, Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering the following categories:

* Swine E. coli Vaccines * Equine Influenza and Tetanus Vaccines * Ruminant Neonatal and Clostridia Vaccines * Rabies Vaccines * Companion Animal Veterinary Specialty Products * Parasiticides & Anti-inflammatories

The acquisition is subject to certain closing conditions, including antitrust approval. Terms of the agreement were not disclosed.

Pfizer Animal Health’s Europe President, Albert Bourla, said that the acquisition will enable Pfizer Animal Health Europe to build upon its comprehensive animal health solutions for veterinarians and their clients - farmers and pet owners - in Europe. Bourla added, “We look forward to offering veterinarians additional preventative therapies and treatments along with our technical expertise and services to ensure that animals receive the best care possible.”

About Pfizer Animal Health

Pfizer Inc (NYSE: PFE - News), the world’s largest research-based pharmaceutical company, is a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Animal Health is dedicated to improving the safety, quality and productivity of the world’s food supply by enhancing the health of livestock and poultry; and in helping companion animals live longer and healthier lives. For additional information on Pfizer’s portfolio of animal products, visit www.PfizerAH.com.

DISCLOSURE NOTICE: The information contained in this release is as of April 23, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the agreement by Pfizer to acquire certain animal health products from Schering-Plough that involve substantial risks and uncertainties. Such risks and uncertainties include, among others, the satisfaction of the conditions to closing the agreement. A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report of Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.